Tego Science, Inc.
Develops cell therapies for skin regeneration, 3D models for testing, and provides CDMO services.
191420 | KO
Overview
Corporate Details
- ISIN(s):
- KR7191420009
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강서구 마곡중앙8로 93 (마곡동, 테고사이언스), 서울특별시
- Website:
- http://www.tegoscience.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Tego Science, Inc. is a biopharmaceutical company specializing in advanced regenerative medicine, leveraging proprietary cell culture technology. Founded in 2001, the company develops, manufactures, and commercializes cell therapies for skin regeneration and wound healing. Its key approved products include Holoderm® for severe burns, Kaloderm® for diabetic foot ulcers, and Rosmir® for wrinkle improvement. Beyond therapeutics, Tego Science offers Neoderm®, a 3D cultured skin model as an alternative to animal testing, and provides Contract Development and Manufacturing Organization (CDMO) services from its GMP facility. The company maintains a robust R&D pipeline, with candidates like TPX-115 for rotator cuff tears, and operates a globally compliant allogeneic cell bank to ensure stable production of its innovative treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-14 00:00 | Interim Report 반기보고서 (2025.06) | Korean | 1.1 MB | ||
| 2025-05-27 00:00 | Share Issue/Capital Change 증권발행결과(자율공시)               | Korean | 5.6 KB | ||
| 2025-05-26 00:00 | Capital/Financing Update [기재정정]주요사항보고서(전환사채권발행결정) | Korean | 111.0 KB | ||
| 2025-05-23 00:00 | Capital/Financing Update 주요사항보고서(전환사채권발행결정) | Korean | 108.1 KB | ||
| 2025-05-14 00:00 | Quarterly Report 분기보고서 (2025.03) | Korean | 1.1 MB | ||
| 2025-03-28 00:00 | Post-Annual General Meeting Information 정기주주총회결과               | Korean | 23.1 KB | ||
| 2025-03-19 00:00 | Audit Report / Information 감사보고서제출               | Korean | 25.0 KB | ||
| 2025-03-19 00:00 | Annual Report 사업보고서 (2024.12) | Korean | 1.4 MB | ||
| 2025-03-06 00:00 | Pre-Annual General Meeting Information 주주총회소집결의               | Korean | 12.2 KB | ||
| 2025-03-06 00:00 | Pre-Annual General Meeting Information 주주총회소집공고 | Korean | 134.4 KB | ||
| 2025-03-06 00:00 | Pre-Annual General Meeting Information 주주총회집중일개최사유신고               | Korean | 4.4 KB | ||
| 2025-03-06 00:00 | Pre-Annual General Meeting Information [기재정정]주주총회소집공고 | Korean | 138.0 KB | ||
| 2025-02-14 00:00 | Report Publication Announcement 기업설명회(IR)개최               | Korean | 6.9 KB | ||
| 2025-02-14 00:00 | Regulatory News Service 투자판단관련주요경영사항(임상시험계획승인신청등결정)              (회전근개 부분층 파열 개선을 위한 동종피부유래섬유아세포(TPX-11… | Korean | 10.2 KB | ||
| 2025-01-31 00:00 | Regulatory News Service 매출액또는손익구조30%(대규모법인은15%)이상변동               | Korean | 11.0 KB | 
Automate Your Workflow. Get a real-time feed of all Tego Science, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Tego Science, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Tego Science, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value | 
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
 
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                    